Tom

Historically, the management of oncology drugs in the U.S. has remained relatively hands-off, despite high budget impact. However, the situation may be changing. Recently, there has been discussion around new management tools, shifting of financial risk, and the influence of value frameworks. In June 2020, Two Labs conducted a panel with payers, hematology and oncology providers, and representatives from several big pharma and small biotech companies with oncology [...]

Launching a drug isn’t easy. All manufacturers, no matter the classification of product they create, face challenges on the journey to bring their drug to market. However, due to the nature of their dose form, complex storage needs, stability requirements, and costs, manufacturers launching specialty drugs must often navigate more hurdles than those dealing with a traditional retail product. Not appropriately planning for or inaccurately handling these hurdles [...]

At Two Labs, we know that our clients are looking for solutions. Every service we offer is about paving the way for our clients to launch their products to the market and into the hands of patients who need them. As we continue to grow, and especially as we evaluate our new reality during and after the COVID-19 pandemic, our focus is on connecting the dots to help [...]